Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis.
R al-Sabbagh , Y Shen , F A Sinicrope , J H Sellin
The American Journal of Gastroenterology 91 ( 9) 1814 -1816
73
1996
Abstract P1-18-04: CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis
NT Ueno , RK Tahara , JM Reuben , H Gao
Cancer Research 79
1
2019
Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non-Muscle Invasive Bladder Cancer
NA Brooks , JT Matulay , R Li , A Kokorovic
Urologic Oncology-seminars and Original Investigations 38 ( 12) 902 -903
2020
Abstract P1-14-07: Association between quantitative values of estrogen receptor expression level and pathological complete response in human epidermal growth factor 2-negative breast cancer: Should the clinical definition of triple-negative breast cancer be redefined?
T Fujii , T Kogawa , W Dong , S Moulder
Cancer Research 76
2016
Abstract P4-20-05: Patient-reported cosmetic outcomes in older breast cancer survivors: A population-based survey study
X Lei , Y Xu , Y Shen , NA Goodwin
Cancer Research 77
2017
Abstract OT1-01-05: A phase II study using talimogene laherparepvec as a single agent for inflammatory breast cancer or non-inflammatory breast cancer patients with inoperable local recurrence
JS Willey , AN Marx , B Lim , NK Ibrahim
Cancer Research 78
2018
Abstract OT3-06-04: A randomized phase II study of neoadjuvant panitumumab /carboplatin/paclitaxel (PaCT) versus carboplatin/paclitaxel (CT) followed by adriamycin and cyclophosphamide (AC) for newly diagnosed primary triple-negative inflammatory breast cancer (TNIBC)
JS Willey , CA Parker , B Lim , V Valero
Cancer Research 78
2018
Abstract P1-16-02: Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis
RK Tahara , T Fujii , B Saigal , NK Ibrahim
Cancer Research 78
2018
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
H M Amin , Y Yang , Y Shen , E H Estey
Leukemia 19 ( 9) 1567 -1572
28
2005
Abstract P6-12-03: Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy
H Masuda , M Chavez-Mac Gregor , DD Liu , RH Alvarez
Cancer Research 73
2013
Abstract P6-12-02: Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer
TM Fouad , T Kogawa , DD Liu , Y Shen
Cancer Research 73
1
2013
Abstract PD03-08: Statin use and improved outcome in primary inflammatory breast cancer: retrospective cohort study
TM Brewer , H Masuda , T Iwamoto , P Liu
Cancer Research 72
2
2012
Statin use in primary inflammatory breast cancer: a cohort study.
T M Brewer , H Masuda , D D Liu , Y Shen
British Journal of Cancer 109 ( 2) 318 -324
66
2013
Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk
CH Ahern , YC T Shih , W Dong , G Parmigiani
British Journal of Cancer 111 ( 8) 1542 -1551
27
2014
Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia
M B Thomas , C Koller , Y Yang , Y Shen
Leukemia 17 ( 5) 990 -993
12
2003
Prognostic significance of cytokine levels in newly-diagnosed AML and high-risk myelodysplasia.
M Albitar , E Estey , D Doherty , Y Shen
Blood 98 ( 11) 327A -327A
2
2001
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis
RKS Phillips , MH Wallace , PM Lynch , E Hawk
Gut 50 ( 6) 857 -860
358
2002
Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis
D Boyce-Fappiano , I Bedrosian , Y Shen , H Lin
NPJ breast cancer 7 ( 1) 87 -87
8
2021
Recovering penile length and erectile function following radical prostatectomy
N Huber , C Wood , R Babaian , L Madsen
J Sex Med 3 ( suppl 1) 32 -32
8
2006
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013: 1: 229-34. 20 Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy
D Ng Tang , Y Shen , J Sun , S Wen
J Clin Oncol 31 2388 -95
5
2013